Protagonist Therapeutics, Inc. (PTGX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Dec 27, 2024

$38.96

P/E Ratio

14.62

Market Cap

$2.32B

Loading...
Description

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Metrics

Overview

  • HQNewark, CA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerPTGX
  • Price$38.96-1.39%

Trading Information

  • Market cap$2.32B
  • Float94.52%
  • Average Daily Volume (1m)690,431
  • Average Daily Volume (3m)663,540
  • EPS$2.82

Company

  • Revenue$323.79M
  • Rev growth (1yr)N/A
  • Net income-$33.21M
  • Gross margin86.16%
  • EBITDA margin-872.86%
  • EBITDA-$40.81M
  • EV$2.32B
  • EV/Revenue7.17
  • P/E14.62
  • P/S7.43
  • P/B4.36
Documents